Volume 19, Number 7—July 2013
Research
Pneumococcal Serotypes before and after Introduction of Conjugate Vaccines, United States, 1999–20111
, Kristopher P. Heilmann, Cassie L. Dohrn, Fathollah Riahi, Daniel J. Diekema, and Gary V. Doern
Table 4
Serotype distribution of pencillin-nonsusceptible noninvasive and invasive pneumococcal isolates, United States, 1999–2011*
| Serotype | No. (%) isolates |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Noninvasive |
Invasive |
||||||||
| Pencillin intermediate and resistant (oral breakpoint), MIC ≥0.12 µg/mL |
Pencillin resistant (meningitis breakpoint), MIC ≥0.12 µg/mL |
||||||||
| Before PCV7, 1999–2000 | Post-PCV7, 2004–2005 | Post-PCV7, 2008–2009 | Post-PCV13, 2010–2011 | Before PCV7, 1999–2000 | Post-PCV7, 2004–2005 | Post-PCV7, 2008–2009 | Post- PCV13, 2010–2011 | ||
| PCV7 | |||||||||
| 4† | 1 (0.3) | 2 (0.5) | 0 | 0 | 1 (0.8) | 0 | 0 | 0 | |
| 6B† | 63 (16.8) | 15 (3.6) | 3 (0.5) | 4 (0.7) | 24 (18.9) | 5 (4.3) | 2 (1.7) | 1 (0.8) | |
| 9V† | 44 (11.8) | 11 (2.6) | 5 (0.8) | 0 | 23 (18.1) | 7 (6.0) | 0 | 0 | |
| 14† | 38 (10.2) | 6 (1.4) | 3 (0.5) | 0 | 33 (26.0) | 3 (2.6) | 1 (0.8) | 0 | |
| 18C† | 2 (0.5) | – | 0 | 0 | 1 (0.8) | 0 | 0 | 0 | |
| 19F† | 85 (22.7) | 56 (13.4) | 38 (6.2) | 27 (4.8) | 10 (7.9) | 12 (10.3) | 2 (1.7) | 1 (0.8) | |
| 23F† | 58 (15.5) | 16 (3.8) | 3 (0.5) | 3 (0.5) | 13 (10.2) | 3 (2.6) | 1 (0.8) | 0 | |
| Total |
291 (77.8) |
106 (25.4) |
52 (8.5) |
34 (6.1) |
105 (82.7) |
30 (25.6) |
6 (5.0) |
2 (1.6) |
|
| Additional serotypes in PCV13 | |||||||||
| 1† | 0 | 1 (0.2) | 0 | 0 | 0 | 0 | 0 | 0 | |
| 3† | 2 (0.5) | 5 (1.2) | 0 | 2 (0.4) | 0 | 1 (0.9) | 0 | 0 | |
| 6A | 17 (4.5) | 32 (7.7) | 17 (2.3) | 3 (0.5) | 6 (4.7) | 17 (14.5) | 2 (1.7) | 1 (0.8) | |
| 7F† | 0 | 6 (1.4) | 0 | 1 (0.2) | 0 | 0 | 1 (0.8) | 1 (0.8) | |
| 19A† | 16 (4.3) | 111 (26.6) | 275 (44.8) | 227 (40.6) | 7 (5.5) | 44 (37.6) | 59 (49.6) | 55 (44.0) | |
| Total |
35 (9.4) |
149 (35.6) |
292 (47.6) |
233 (41.7) |
13 (10.2) |
62 (53.0) |
62 (52.1) |
57 (45.6) |
|
| PCV-related | |||||||||
| 6C | 3 (0.8) | 12 (2.9) | 61 (9.9) | 63 (11.3) | 1 (0.8) | 2 (1.7) | 13 (10.9) | 14 (11.2) | |
| 9A | 2 (0.5) | 4 (1.0) | 2 (0.3) | 1 (0.2) | 4 (3.2) | 0 | 1 (0.8) | 1 (0.8) | |
| 19B | 0 | 0 | 0 | 1 (0.2) | 0 | 1 (0.9) | 1 (0.8) | 0 | |
| 23A | 2 (0.5) | 13 (3.1) | 39 (6.4) | 37 (6.6) | 0 | 4 (3.4) | 13 (10.9) | 19 (15.2) | |
| 23B | 0 | 5 (1.2) | 12 (2.0) | 7 (1.3) | 0 | 0 | 1 (0.8) | 6 (4.8) | |
| Other | 2 (0.5)‡ | 2 (0.5)§ | 1 (0.2)¶ | 2 (0.4)# | 0 | 0 | 0 | 0 | |
| Total |
9 (2.4) |
36 (8.6) |
115 (18.7) |
111 (19.9) |
5 (3.9) |
7 (6.0) |
29 (24.4) |
40 (32.0) |
|
| Non-PCV | |||||||||
| 11A† | 0 | 5 (1.2) | 2 (0.3) | 7 (1.3) | 0 | 1 (0.9) | 0 | 0 | |
| 15A | 3 (0.8) | 27 (6.5) | 56 (9.1) | 29 (5.1) | 0 | 8 (6.8) | 9 (7.6) | 11 (8.8) | |
| 15B† | 0 | 1 (0.2) | 6 (1.0) | 22 (3.9) | 0 | 0 | 1 (0.8) | 0 | |
| 15C | 0 | 3 (0.7) | 7 (1.1) | 12 (2.1) | 0 | 0 | 3 (2.5) | 1 (0.8) | |
| 35B | 19 (5.1) | 56 (13.4) | 56 (9.1) | 89 (15.9) | 1 (0.8) | 5 (4.3) | 7 (5.9) | 13 (10.4) | |
| Other |
4 (1.1)** |
26(6.2)†† |
19 (3.1)‡‡ |
11 (2.0)§§ |
1 (0.8)** |
2 (1.7)†† |
2 (1.7)‡‡ |
0 |
|
| NT |
13 (3.5) |
9 (2.2) |
9 (1.4) |
11 (2.0) |
2 (1.6) |
2 (1.7) |
0 |
1 (0.8) |
|
| Total |
39 (10.4) |
127 (30.4) |
155 (25.2) |
181 (32.4) |
4 (3.1) |
18 (15.4) |
22 (18.5) |
26 (20.8) |
|
| All serotypes | 374 | 418 | 614 | 559 | 127 | 117 | 119 | 125 | |
*PCV7, pneumococcal conjugate 7-valent vaccine; PCV13, pneumococcal conjugate 13-valent vaccine; NT, nontypeable; non, noninvasive; inv, invasive.
†Serotypes in 23-valent polysaccharide pneumococcal vaccine.
‡Other low prevalence serotypes (no. isolates): in 1999–2000, serotype 9N (1 non), 18 F (1 non).
§In 2004–2005, serotype 18B (1 non), 19C (1 non).
¶In 2008–2009, serotype 9N (1 non).
#In 2010–2011, serotype 7C (1 non), 9N (1 non).
**In 1999–00, serotype 16F (2 non), 22F (1 non), 29 (1 non, 1 inv).
††In 2004–2005, serotype 15F (1 non), 16F (1 non), 20 (1 non), 21 (1 non), 22F (1 inv), 29 (8 non), 31 (1 non), 33F (1 inv), 35A (9 non), 35F (2 non), 39 (1 non), 48 (1 non).
‡‡In 2008–09, serotype 8 (1 non), 11D (1 non), 17F (2 non), 21 (1 non), 22F (1 inv), 22A (1 non), 25A (1 non), 29 (6 non, 1 inv), 33F (1 non), 34 (1 non), 35A (1 non), 42 (3 non).
§§In 2010–11, serotype 16F (2 non), 21 (2 non), 29 (1 non), 31 (2 non), 33F (1 non), 34 (1 non), 38 (2 non).
1Presented in part at the 112th General Meeting of the American Society for Microbiology Annual Meeting, June 19, 2012, San Francisco, CA, USA (abstract no. 2986).